Danazol Capsules

1. It is a gonadotropin inhibitor that can inhibit the pituitary-ovarian axis. 2. Due to the inhibition of pituitary gonadotropin, the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) is reduced. 3. It can directly inhibit the production of ovarian steroid hormones, act on the estrogen receptor sites of endometrial cells, and have the effect of inhibiting estrogen, causing normal and abnormal endometrium of the uterus to atrophy and become inactive, leading to anovulation and amenorrhea, which can last up to 6-8 months. 4. In the treatment of fibrous breast disease, it can make nodules disappear, relieve pain and tenderness, and may cause menstrual disorders or amenorrhea. 5. In the treatment of hereditary angioedema, it increases the level of serum C1 lipase inhibitor, leading to an increase in the concentration of C4 in the complement system in the serum.

The main ingredient of this product is danazol. Its chemical name is 17-pregnane-2,4-diene-20-yn-[2,3-d]isoxazol-17-ol. Molecular formula: C22H37NO2 Molecular weight: 337.46

The content of this product is white or off-white crystals or crystalline powder.

It is used to treat endometriosis, and can also be used to treat fibrocystic breast disease, spontaneous thrombocytopenic purpura, hereditary angioedema, systemic erythema, male gynecomastia, and precocious puberty.

Common oral dosage for adults: 1. Endometriosis, 400-800 mg per day, divided into two doses, for 3-6 months. If symptoms reappear after stopping the drug, another course of treatment can be given (under normal liver function). 2. Fibrocystic breast disease, take the drug on the first day after the start of menstruation, 50-200 mg once, twice a day. If symptoms recur within one year after stopping the drug, the drug can be given again. 3. Hereditary angioedema, start with 200 mg once, 2-3 times a day, until the effect appears. The maintenance dose is generally 50% or less of the starting dose, and it is decreased at intervals of 1-3 months or longer, depending on the frequency of the disease before treatment.

1. Common adverse reactions: amenorrhea, breakthrough uterine bleeding, and possible breast reduction, hoarseness, and increased hair growth; acne, increased oiliness of the skin or hair, lower limb edema, or weight gain may occur. The symptoms are related to the dosage and are manifestations of androgen effects. 2. Less common adverse reactions: hematuria, epistaxis, gingival bleeding, cataracts (gradually blurred vision), abnormal liver function, increased intracranial pressure (manifested as severe headache, decreased vision, diplopia, vomiting), leukocytosis, acute pancreatitis, multiple neuritis, etc. 3. Rare adverse reactions include: enlarged clitoris in women and reduced testicles in men; when liver function is severely impaired, both men and women may experience yellowing of the sclera or skin. 4. The following reactions should be noted if they continue to occur: (1) Due to low estrogen efficacy, women may experience vaginal burning, dryness and itching, or vaginal bleeding. (2) Redness of the skin, changes in mood or mental state, nervousness, or excessive sweating may occur.

It is contraindicated for patients with thrombosis, heart, liver, and kidney diseases, and abnormal genital bleeding.

Precautions for children: This experiment has not been conducted and there are no reliable references. Precautions for pregnancy and lactation: Pregnant women should not use this drug. Pregnant women who are taking the drug should terminate the pregnancy. Theoretically, this product may have androgenic effects on female fetuses, and lactating women should not take it. Precautions for the elderly: Generally, elderly patients have low physiological functions and should take a reduced dose (such as 100mg-200mg per day).

1. When used together with insulin, it is easy to produce drug resistance; 2. When used together with warfarin, the anticoagulant effect is enhanced and bleeding is easy to occur.

Keep away from light and store in sealed container.

0.1g

Three years

Zhejiang Xianju Pharmaceutical Co., Ltd.

• Founded in:

  2000-06-26

• Address:

  No. 1, Xianyao Road, Xianju County, Taizhou City, Zhejiang Province

• Tax NO.:

  913300007047892221

• Registered Funds:

  989.204866 million yuan

• Website:

  Log in to view

• Email:

  Log in to view